Literature DB >> 14557145

Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial.

Paul B Fitzgerald1, Timothy L Brown, Natasha A U Marston, Z Jeff Daskalakis, Anthony De Castella, Jayashri Kulkarni.   

Abstract

BACKGROUND: High-frequency left-sided repetitive transcranial magnetic stimulation (HFL-TMS) has been shown to have antidepressant effects in double-blind trials. Low-frequency stimulation to the right prefrontal cortex (LFR-TMS) has also shown promise, although it has not been assessed in treatment-resistant depression and its effects have not been compared with those of HFL-TMS.
OBJECTIVE: To prospectively evaluate the efficacy of HFL-TMS and LFR-TMS in treatment-resistant depression and compared with a sham-treated control group.
DESIGN: A double-blind, randomized, sham-controlled trial.
SETTING: Two general psychiatric services. PARTICIPANTS: Sixty patients with treatment-resistant depression who had failed to respond to therapy with multiple antidepressant medications were divided into 3 groups of 20 that did not differ in age, sex, or any clinical variables. All patients completed the double-blind phase of the study.
INTERVENTIONS: Twenty 5-second HFL-TMS trains at 10 Hz and five 60-second LFR-TMS trains at 1 Hz were applied daily. Sham stimulation was applied with the coil angled at 45 degrees from the scalp, resting on the side of one wing of the coil. Main Outcome Measure Score on the Montgomery-Asberg Depression Rating Scale.
RESULTS: There was a significant difference in response among the 3 groups (F56,2 = 6.2), with a significant difference between the HFL-TMS and sham groups and between the LFR-TMS and sham groups (P<.005 for all) but not between the 2 treatment groups. Baseline psychomotor agitation predicted successful response to treatment.
CONCLUSIONS: Both HFL-TMS and LFR-TMS have treatment efficacy in patients with medication-resistant major depression. Treatment for at least 4 weeks is necessary for clinically meaningful benefits to be achieved. Treatment with LFR-TMS may prove to be an appropriate initial repetitive TMS strategy in depression taking into account safety, tolerability, and efficacy considerations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557145     DOI: 10.1001/archpsyc.60.9.1002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  74 in total

Review 1.  Brain stimulation in psychiatry and its effects on cognition.

Authors:  Kate E Hoy; Paul B Fitzgerald
Journal:  Nat Rev Neurol       Date:  2010-04-06       Impact factor: 42.937

2.  Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression.

Authors:  Alexander McGirr; Sneha Karmani; Rashmi Arsappa; Marcelo T Berlim; Jagadisha Thirthalli; Kesavan Muralidharan; Lakshmi N Yatham
Journal:  World Psychiatry       Date:  2016-02       Impact factor: 49.548

3.  [Brain stimulation procedures. Transcranial magnetic stimulation, magnetic seizure therapy and deep brain stimulation].

Authors:  T E Schläpfer; S Kayser
Journal:  Nervenarzt       Date:  2012-01       Impact factor: 1.214

4.  Repetitive transcranial magnetic stimulation for the treatment of depression: to stimulate or not to stimulate?

Authors:  Zafiris J Daskalakis
Journal:  J Psychiatry Neurosci       Date:  2005-03       Impact factor: 6.186

5.  Antidepressant Effect of 58 Sessions of rTMS in a Pregnant Woman With Recurrent Major Depressive Disorder: A Case Report.

Authors:  Oguz Tan; Nevzat Tarhan; Adnan Coban; Semra Kaya Baripoglu; Funda Guducu; Hasan Basri Izgi; Gokben Hizli; Oznur Ates; Huseyin Bulut
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 6.  Potential role of repetitive transcranial magnetic stimulation in obesity.

Authors:  Rami Bou Khalil; Charline El Hachem
Journal:  Eat Weight Disord       Date:  2013-12-11       Impact factor: 4.652

7.  Prelimbic Cortical Injections of a GABA Agonist and Antagonist: In Vivo Quantification of the Effect in the Rat Brain Using [(18)F] FDG MicroPET.

Authors:  Joke Parthoens; Stijn Servaes; Jeroen Verhaeghe; Sigrid Stroobants; Steven Staelens
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 8.  Developing Collaborative Platforms to Advance Neurotechnology and Its Translation.

Authors:  David A Borton; Heather E Dawes; Gregory A Worrell; Philip A Starr; Timothy J Denison
Journal:  Neuron       Date:  2020-10-28       Impact factor: 17.173

Review 9.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 10.  Novel targets for antidepressant therapies.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.